Comparative Bioavailability of Risperidone

Completed · Phase 1

Conditions studied: Schizophrenia

In brief

This is an open-label, one sequence study to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once daily 4 mg oral risperidone in subjects with schizophrenia stabilized on oral risperidone treatment.

Key facts

Study ID

NCT03527186

Run by

Rovi Pharmaceuticals Laboratories

People needed

81

Starts

2018-07-09

Expected to finish

2019-04-06

Last updated by the study team

2021-12-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Collaborative Neuroscience Network — Long Beach, California, United States
• Hassman Research Institute — Berlin, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.